Precision at scale: Sapian expands to 13.6 Billion Compounds

Kantify's AI drug discovery platform expands chemical space while maintaining precision

Sapian, Kantify's AI-powered virtual screening engine, has expanded its compound screening capacity to 13.6 billion molecules, aligning with the latest expansion of the Enamine REAL database. This expansion represents a significant milestone in accessible chemical space for drug discovery programs, though the true value lies beyond the numbers.

Balancing Coverage and Selectivity

Chemical space exploration in drug discovery faces two competing challenges: coverage must be sufficiently broad to identify novel structural classes, yet selective enough to yield tractable candidates. The expansion to 13.6 billion compounds addresses the coverage dimension, providing researchers with unprecedented access to potential therapeutic molecules.

The critical advancement, however, lies in Sapian's ability to navigate this expanded space fast and effectively. While the computational burden of screening billions of compounds represents a fundamental technological barrier that typically constrains processing speed, Sapian's architecture was designed from first principles to overcome this limitation and scale efficiently without compromising prediction quality.

Precision Over Volume

What distinguishes meaningful progress in AI-powered virtual screening is not the raw compound count, but the precision with which the system identifies molecules with a strictly defined pharmacological profile. This requires accurate prediction of binding potential, ADMET properties, selectivity (...) — areas where the mere volume of compounds offers no inherent advantage.

Where some approaches face diminishing returns as libraries expand, our validation metrics demonstrate that Sapian's performance remains robust across the entire 13.6 billion compound space.

Validated Performance at Scale

Kantify's validation protocols continue to demonstrate that Sapian maintains its predictive power across this expanded chemical space. The increased coverage allows exploration of previously inaccessible regions of chemical space while maintaining the discrimination capability essential for identifying viable leads.

Looking Forward

Sapian will continue expanding to wider libraries.

However, the ultimate measure remains downstream experimental success: compounds that perform as predicted in biochemical assays, demonstrate the expected properties in cellular models, and eventually benefit patients.

Scale, in Sapian's design philosophy, serves this purpose: enabling better outcomes.